Sam Hancock

Sam Hancock

M.Sci. Genetics

Sam completed his MSci in Genetics at the University of Nottingham in 2019, fuelled initially by an interest in genetic ageing. As part of his degree, he also investigated the role of rnh genes in originless replication in archaea.

Articles from Sam

COVID mRNA vaccines display weakened immune response with age and diminish over time, according to new study

COVID mRNA vaccines display weakened immune response with age and diminish over time, according to new study

15 Sep 2021
Phase I trial investigates using antiparasitic nitazoxanide for treatment of COVID-19

Phase I trial investigates using antiparasitic nitazoxanide for treatment of COVID-19

15 Sep 2021
The Indian second wave: SARS-CoV-2 infection-induced immunity could be ineffective in protecting population

The Indian second wave: SARS-CoV-2 infection-induced immunity could be ineffective in protecting population

15 Sep 2021
SARS-CoV-2 variants show substantial differences in spike structure

SARS-CoV-2 variants show substantial differences in spike structure

15 Sep 2021
Urban and deprived individuals are disproportionately afflicted by COVID-19

Urban and deprived individuals are disproportionately afflicted by COVID-19

13 Sep 2021
The comparative effectiveness of neutralizing monoclonal antibodies against SARS-CoV-2

The comparative effectiveness of neutralizing monoclonal antibodies against SARS-CoV-2

13 Sep 2021
An oral COVID-19 vaccine induces mucosal and protective immunity

An oral COVID-19 vaccine induces mucosal and protective immunity

13 Sep 2021
As COVID restrictions were removed, Texas saw an increase in seasonal respiratory virus infections

As COVID restrictions were removed, Texas saw an increase in seasonal respiratory virus infections

13 Sep 2021
No evidence of pre-existing antibody and B cell immunity against SARS-CoV-2 in unexposed adults

No evidence of pre-existing antibody and B cell immunity against SARS-CoV-2 in unexposed adults

10 Sep 2021
Virus-like nanoparticle vaccine effective against SARS-CoV-2 in animal model

Virus-like nanoparticle vaccine effective against SARS-CoV-2 in animal model

10 Sep 2021

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback